{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-21-021383","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2021-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.866780+00:00","generated_at":"2026-06-29T05:58:28.086921+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Integrated BioPharma reports FY net income $8.0M, revenue up 20.5% YoY","bullets":["Revenue for FY ended June 30, 2021: $63.6M, up 20.5% YoY from $52.8M.","FY net income $8.0M ($0.27 basic EPS) vs $4.1M ($0.14 basic EPS) prior year.","Q4 revenue $17.1M (+26.7% YoY); Q4 net income $4.5M ($0.15 basic EPS) vs $1.9M ($0.06).","FY operating income $5.8M vs $3.3M prior year; PPP forgiveness of $1.7M boosted other income.","Two customers represent ~92% of total revenue in both FY2021 and FY2020, per co-CEOs."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-21-021383","json":"https://secwatch.observer/filing/0001437749-21-021383.json","markdown":"https://secwatch.observer/filing/0001437749-21-021383.md","text":"https://secwatch.observer/filing/0001437749-21-021383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774921021383/0001437749-21-021383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774921021383/inbp20210902_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T05:58:28.086921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}